Welcome
Support Centre
21 March 2013 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   news
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes
statistics

[ Print-friendly version ]
Evaluation of the efficacy of oxybutynin and imipramine in the management of detrusor instability
ISRCTN ISRCTN58226681
DOI 10.1186/ISRCTN58226681
ClinicalTrials.gov identifier
EudraCT number
Public title Evaluation of the efficacy of oxybutynin and imipramine in the management of detrusor instability
Scientific title
Acronym N/A
Serial number at source G9410491
Study hypothesis To investigate the efficacies of oxybutynin and imipramine in the treatment of detrusor instability. A pragmatic trial titrating dose against effect and side effects. All patients continuing with bladder education.
Lay summary Not provided at time of registration
Ethics approval Not provided at time of registration
Study design Randomised controlled trial
Countries of recruitment United Kingdom
Disease/condition/study domain Incontinence
Participants - inclusion criteria 1. Failed conservative therapies for urinary dysfunction (nursing interventions)
2. Urodynamicaly proven detrusor instability
Participants - exclusion criteria 1. Pregnancy
2. Malignancy
3. Fistula
4. Contra-indications to the use of oxybutynin or imipramine
5. Bladder outflow obstruction (measured urodynamically)
Anticipated start date 01/06/1997
Anticipated end date 01/09/2001
Status of trial Completed
Patient information material Not available in web format, please use the contact details below to request a patient information sheet
Target number of participants 345
Interventions 1. Oxybutynin: Oxybutynin titrated to a maximum dose of 5 mg tds and imipramin placebo
2. Imipramine: Imipramine titrated to a maximum dose of 75 mg bd and Oxybutynin placebo
3. Control: matching placebo tablets of Imipramine and Oxybutynin
Primary outcome measure(s) Clinical assessment using urinary diaries and 24 hour home pad tests.
Secondary outcome measure(s) Not provided at time of registration
Sources of funding Medical Research Council (MRC) (UK)
Trial website
Publications
Contact name Dr  C  McGrother
  Address Department of Epidemiology and Public Health
University of Leicester
22-28 Princess Road West
  City/town Leicester
  Zip/Postcode LE1 2TP
  Country United Kingdom
  Email
Sponsor Medical Research Council (MRC) (UK)
  Address 20 Park Crescent
  City/town London
  Zip/Postcode W1B 1AL
  Country United Kingdom
  Tel +44 (0)20 7636 5422
  Fax +44 (0)20 7436 6179
  Email clinical.trial@headoffice.mrc.ac.uk
  Sponsor website: http://www.mrc.ac.uk
Date applied 25/10/2000
Last edited 06/06/2012
Date ISRCTN assigned 25/10/2000
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2013 ISRCTN unless otherwise stated.